Samsung Biologics Achieves ‘Leadership’ Status in CDP Water Security Rating

• Samsung Biologics has been awarded ‘Leadership’ status with an A- rating for water security by the Carbon Disclosures Project (CDP).

Samsung Biologics has received an A- rating for water security from the Carbon Disclosures Project (CDP), achieving ‘Leadership’ status in its first year of participation. The recognition highlights the company’s commitment to efficient water resource management as part of its broader environmental, social, and governance (ESG) strategy.

CDP, a non-profit organisation, evaluates over 24,800 companies worldwide on corporate environmental transparency and sustainability performance. The rating acknowledges Samsung Biologics’ initiatives to manage water pollution and consumption while enhancing operational resilience.

“As a sustainable CDMO, we are continuously striving to incorporate ESG principles into our operations to help achieve our net zero transition and provide more sustainable services,” said John Rim, CEO and President of Samsung Biologics. “We are also working alongside leading global pharma companies to encourage our suppliers to build sustainable supply chains and contribute to driving change across the healthcare industry.”

The company plays a key role in the Sustainable Markets Initiative (SMI) Health Systems Task Force, where it collaborates with public and private sector entities to promote sustainability in healthcare supply chains. It has signed renewable Power Purchase Agreements (PPAs) to advance its transition to clean energy and continues to refine its water resource management strategies.

Samsung Biologics aims to achieve net zero by 2050, implementing measures such as Product Carbon Footprint tracking, high-efficiency boilers, and solar panel installations. The company remains committed to minimising its environmental impact by optimising water-use efficiency and integrating low-carbon technologies across its operations.